AMENDMENTS TO THE CLAIMS

This listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A compound having Formula I, or a pharmaceutically acceptable salt thereof, wherein



I

R^1 and R^2 are each C_1-C_3 alkyl, which are optionally substituted with 1-5 halogens independently selected from F and Cl;

R^3 is selected from the group consisting of

(a) H, and

(b) C_1-C_3alkyl, which is optionally substituted with 1-5 halogens independently selected from F and Cl;

R^4 is C_1-C_3 alkyl, which is optionally substituted with 1-5 halogens independently selected from F and Cl;

R^5 is selected from the group consisting of H and C_1-C_3alkyl, which is optionally substituted with 1-5 halogens independently selected from F and Cl;

R^6 is selected from H, Cl, CH_3 and CF_3;

R^7 is selected from H and C_1-C_3 alkyl, which is optionally substituted with 1-5 halogens independently selected from F and Cl;

A and B are each selected from H, Cl, F, CH_3, and CF_3;

The dashed line connecting the ring carbon atoms attached to R^5 and R^7 is an optional double bond;

X and Y are independently selected from O and S; and

n is an integer from 2-3.

2. (original) A compound according to Claim 1, wherein X and Y are each O.

3. (original) A compound according to Claim 1, wherein A, B, and R^7 are H.

4. (original) A compound according to Claim 1, wherein R^5 is CF_3.

5. (original) A compound according to Claim 1, wherein R^5 is C_1-C_3 alkyl.

6. (original) A compound according to Claim 1, wherein R^6 is selected from Cl, CH_3 and CF_3.

7. (original) A compound according to Claim 6, wherein R^6 is Cl.

8. (original) A compound according to Claim 1, wherein R^3 and R^4 are each independently selected from CH_3, C_2H_5, and C_3H_7.

9. (original) A compound according to Claim 1, wherein R^1 and R^2 are each selected from CH_3 and C_2H_5.

10. (original) A compound according to Claim 9, wherein R^1 and R^2 are each CH_3.

11. (original) A compound according to Claim 1, wherein

R^1 and R^2 are each independently selected from the group consisting of CH_3 and C_2H_5;

R3 and R4 are each independently selected from the group consisting of CH3, C2H5, and C3H7;

R^5 is CF3 ;

R^6 is Cl;

R^7, A, and B are H;

The dashed line connecting the ring carbon atoms attached to R5 and R7 is a double bond;

X and Y are O; and

n is an integer from 2-3.

12. (original) A compound according to Claim 11, wherein R^1 and R^2 are each CH_3.

13. (original) A compound according to Claim 1, having the formula shown below, or a pharmaceutically acceptable salt thereof:


CF3
Cl
O
O
O
O
O
OH


CF3
Cl
O
O
O
O
O
OH


CF3
Cl
O
O
O
O
O
OH


CF3
Cl
O
O
O
O
O
OH


Cl
O
O
O
O
O
OH









14. (original) A pharmaceutical composition comprising a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Claim 15 cancelled

16. (original) A method for treating one or more lipid disorders, selected from the group consisting of dyslipidemia, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, low HDL levels, and high LDL levels in a patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of Claim 1.

Claims 17-27 cancelled

28. (original) A pharmaceutical composition comprising (1) a compound according to Claim 1, (2) one or more compounds selected from the group consisting of :

(a) PPARγ agonists and partial agonists;
(b) PPARα/γ dual agonists;
(c) other PPARα agonists;
(d) PPARδ agonists;
(e) Biguanides;
(f) protein tyrosine phosphatase-1B (PTP-1B) inhibitors;
(g) dipeptidyl peptidase IV (DP-IV) inhibitors;
(h) insulin or insulin mimetics;
(i) sulfonylureas;
(j) α-glucosidase inhibitors;
(k) glucagon receptor antagonists;
(l) glycogen phosphorylase inhibitors;
(m) 11-Beta-HSD type 1 enzyme inhibitors;
(n) 11-Beta-HSD type 1 receptor antagonists;
(o) exendin-4, exendin-3, GLP-1, GLP-1 mimetics, and GLP-1 receptor agonists;
(p) GIP, GIP mimetics, and GIP receptor agonists;
(q) PACAP, PACAP mimetics, and PACAP receptor 3 agonists;
(r) HMG-CoA reductase inhibitors;
(s) Bile acid sequestrants;
(t) nicotinyl alcohol, nicotinic acid or a salt thereof;
(u) ezetimibe and other inhibitors of cholesterol absorption;
(v) acyl CoA:cholesterol acyltransferase inhibitors (ACAT inhibitors);
(w) phenolic anti-oxidants;
(x) ileal bile acid transporter inhibitors;
(y) agents intended for use in the treatment of inflammatory conditions;
(z) antiobesity compounds;
(aa) thyroid hormone mimetics;

(bb) LXR agonists;

(cc) FXR agonists;

(dd) PLTP inhibitors;

(ee) CETP inhibitors;

(ff) glucocorticoids; and

(gg) TNF sequestrants; and

(3) a pharmaceutically acceptable carrier.